These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33547737)

  • 1. Comprehensive characterization of the peroxisome proliferator activated receptor-δ agonist GW501516 for horse doping control analysis.
    Trevisiol S; Moulard Y; Delcourt V; Jaubert M; Boyer S; Tendon S; Haryouli H; Taleb W; Caroff M; Chabot B; Drif L; André F; Garcia P; Loup B; Popot MA; Bailly-Chouriberry L
    Drug Test Anal; 2021 Jun; 13(6):1191-1202. PubMed ID: 33547737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS.
    Kintz P; Ameline A; Gheddar L; Raul JS
    Drug Test Anal; 2020 Jul; 12(7):980-986. PubMed ID: 32298044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, mass spectrometric characterization, and analysis of the PPARδ agonist GW1516 and its major human metabolites: targets in sports drug testing.
    Thevis M; Möller I; Beuck S; Schänzer W
    Methods Mol Biol; 2013; 952():301-12. PubMed ID: 23100242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic study of GW1516 in equine urine using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry for doping control.
    Ishii H; Shibuya M; Leung GN; Yamashita S; Yamada M; Kushiro A; Kasashima Y; Okada J; Kawasaki K; Kijima-Suda I
    Rapid Commun Mass Spectrom; 2021 Mar; 35(5):e9028. PubMed ID: 33319421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).
    Pokrywka A; Cholbinski P; Kaliszewski P; Kowalczyk K; Konczak D; Zembron-Lacny A
    J Physiol Pharmacol; 2014 Aug; 65(4):469-76. PubMed ID: 25179079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid investigating of phase I metabolites of SR9009 in vitro horse liver microsomes via feature-based molecular networking approach: Potential applications in doping control.
    Kwak YB; Yoon J; Yoo HH
    J Pharm Biomed Anal; 2024 Aug; 246():116190. PubMed ID: 38735208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha.
    Han S; Ritzenthaler JD; Sun X; Zheng Y; Roman J
    Am J Respir Cell Mol Biol; 2009 Mar; 40(3):325-31. PubMed ID: 18776129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and excretion of the benzodiazepine analogue etizolam in the horse.
    Johnson E; van Heemst J; Benavides J; Gray B
    Drug Test Anal; 2021 Mar; 13(3):583-594. PubMed ID: 33169539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolism of the REV-ERB agonist SR-9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples.
    Cutler C; White DL; Viljanto M
    Drug Test Anal; 2022 Jan; 14(1):169-174. PubMed ID: 34224639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo metabolism of the anabolic-androgenic steroid oxandrolone in the horse.
    Harding C; Viljanto M; Cutler C; Habershon-Butcher J; Biddle S; Scarth J
    Drug Test Anal; 2022 Jan; 14(1):39-55. PubMed ID: 34378336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of the metabolism of the selective androgen receptor modulator LGD-4033 in equine urine, plasma and hair following oral administration.
    Cutler C; Viljanto M; Hincks P; Habershon-Butcher J; Muir T; Biddle S
    Drug Test Anal; 2020 Feb; 12(2):247-260. PubMed ID: 31655494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic study of androsta-1,4,6-triene-3,17-dione in horses using liquid chromatography/high resolution mass spectrometry.
    Kwok WH; Leung GN; Wan TS; Curl P; Schiff PJ
    J Steroid Biochem Mol Biol; 2015 Aug; 152():142-54. PubMed ID: 26031748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and longitudinal distribution of GW1516 and its metabolites in equine hair for doping control using liquid chromatography/high-resolution mass spectrometry.
    Ishii H; Shibuya M; Leung GN; Nozawa S; Yamashita S; Yamada M; Kushiro A; Kasashima Y; Okada J; Kawasaki K; Kijima-Suda I
    Rapid Commun Mass Spectrom; 2021 Apr; 35(8):e9050. PubMed ID: 33470485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
    Serrano-Marco L; Barroso E; El Kochairi I; Palomer X; Michalik L; Wahli W; Vázquez-Carrera M
    Diabetologia; 2012 Mar; 55(3):743-51. PubMed ID: 22179221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells.
    Péchery A; Fauconnet S; Bittard H; Lascombe I
    Tumour Biol; 2016 Nov; 37(11):14789-14802. PubMed ID: 27638828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The peroxisome proliferator-activated receptor β/δ (PPARβ/δ) agonist GW501516 prevents TNF-α-induced NF-κB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.
    Barroso E; Eyre E; Palomer X; Vázquez-Carrera M
    Biochem Pharmacol; 2011 Feb; 81(4):534-43. PubMed ID: 21146504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of bioactive peptides including gonadotrophin-releasing factors (GnRHs) in horse urine using ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC/HRMS).
    Kwok KY; Choi TLS; Kwok WH; Lau MY; Leung EMK; Leung GNW; Wong JKY; Wan TSM; Adrian FF; Prabhu A; Ho ENM
    Drug Test Anal; 2020 Sep; 12(9):1274-1286. PubMed ID: 32558326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine.
    Sobolevsky T; Dikunets M; Sukhanova I; Virus E; Rodchenkov G
    Drug Test Anal; 2012 Oct; 4(10):754-60. PubMed ID: 22977012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.